Lung cancer is the leading cause of cancer death in the U.S., and black patients experience higher lung cancer incidence and mortality than white patients.1 Lung cancer screening facilitates diagnoses at earlier, more treatable stages. In 2011, low-dose computed tomography (LDCT) showed a relative reduction in lung cancer-specific mortality by 20% in the National Lung Screening Trial (NLST), a multisite RCT comparing LDCT and chest radiography for lung cancer screening (n=53,454).2 NLST results indicated that LDCT reduces lung cancer mortality in all racial groups, but a stronger effect was observed among black patients.
